ARCHIVES

Remaining DCT Recompetitions

This article is from The Cancer Letter archive.

Vol. 06 No. 44 | November 7, 1980

Download PDF Visit The Full Archive

Related Articles

Carfilzomib Demonstrates Clinical Benefit Rate of 64%

December 30, 2011

Kington Named Acting NIH Director.

November 14, 2008

Minority Based CCOP RFA Generate Wide Interest; 44 Letters Of Intent Received for Eight Awards

September 1, 1989

Six Compounds Carcinogenic, Risk to Humans, CH Subgroup Finds

February 2, 1979

Lilly Made False Claims About Ralozifene Reducing Breast Cancer risk, Judge Rules

July 30, 1999

Push to Get Exceptions, Adjustments For Clinical Research In DRG Regulations Gaining Momentum

July 22, 1983